Novo Nordisk: Leading bank downgrades drug marker, shares down 2%

Morgan Stanley downgraded Novo Nordisk to underweight, cutting its price target to DKr 300, citing slowing US prescription growth for its blockbuster GLP-1 drugs amid rising competition from Eli Lilly's Mounjaro and the emergence of generics and compounded alternatives. The bank forecasts 5% annual sales growth for 2026-2027, below consensus, and highlights significant future price pressure from potential US Medicare cuts for Ozempic, which collectively threaten Novo's premium valuation despite pipeline developments, causing shares to fall 2%.

Analysis

Morgan Stanley's downgrade of Novo Nordisk (NVO) to 'underweight' with a price target reduction to DKr 300 from DKr 380 highlights a confluence of significant headwinds for the company's blockbuster GLP-1 franchise. The primary concern is the flattening of U.S. prescription volumes for Wegovy, Ozempic, and Rybelsus, which contrasts sharply with the continued growth of Eli Lilly's competing drug, Mounjaro. This competitive pressure informs Morgan Stanley's forecast of 5% annual sales growth for 2026-2027, notably below the 8% consensus. The thesis is further reinforced by mounting pricing and generic threats, including the expected launch of generic Ozempic in Canada and emerging markets, market share erosion from compounded GLP-1 drugs in the U.S., and a projected 50% price reduction for Ozempic under U.S. Medicare starting in 2027. While Novo's pipeline includes oral Wegovy and CagriSema, the bank suggests jejich financial contributions may be neutralized by these pricing pressures. The downgrade ultimately signals a potential de-rating of Novo's valuation, as its target price implies an 11x 2028 earnings multiple, aligning it with slower-growth pharmaceutical peers and questioning the sustainability of its long-held growth premium.

Key Decisions for Investors

• Investors should closely monitor weekly U.S. prescription data for Novo's GLP-1 drugs versus Eli Lilly's Mounjaro to validate the thesis of slowing growth and market share erosion.
• Re-evaluate valuation models for Novo Nordisk, as the stock's premium multiple is under significant threat from decelerating growth, intensifying competition, and forthcoming price cuts.
• Pay close attention to two key near-term catalysts: the U.S. government's Medicare price announcement for Ozempic by November and the binary outcome of the semaglutide Alzheimer's trial, which Morgan Stanley assigns a low probability of success.
• Consider the relative strength of Eli Lilly, which the report positions as a direct beneficiary of Novo's challenges, potentially warranting a review of portfolio allocations within the GLP-1 space.